What Are the Signs That You May Need Hormone Replacement Therapy?

A Complete, Practical Guide From Menopause Specialist Dr. Deepali Kashyap

One of the most common questions women ask me is:

"How do I know whether I actually need hormone replacement therapy?"

The question usually comes after several changes have appeared at once. A woman may be waking repeatedly at night, having hot flashes during work, feeling unusually irritable, struggling to concentrate, gaining weight, or avoiding intimacy because sex has become uncomfortable.

It is understandable that she wants one clear answer.

But there is no single symptom, birthday, hormone result, or online checklist that can prove a woman needs HRT.

A hot flash does not automatically mean you need estrogen. Poor sleep does not automatically mean you need progesterone. Low energy does not automatically mean you need testosterone. Weight gain in your 40s or 50s does not prove that hormones are the only issue.

The question I find more useful is:

Are symptoms associated with perimenopause, menopause symptoms, or early loss of ovarian function affecting your health or quality of life, and is hormone therapy a safe and appropriate way to treat those particular symptoms?

For the right woman, hormone therapy can make an enormous difference. It is the most effective treatment available for bothersome hot flashes and night sweats, according to both The Menopause Society and ACOG. It can also treat vaginal and urinary tissue changes and help protect bone in appropriately selected women.

However, HRT is not one standard prescription, and it is not the correct answer for every physical, emotional, sexual, or metabolic change that occurs during midlife.

In this guide, I will explain the decision in the same sequence I use with patients: what HRT is, which symptoms are most likely to benefit, the different types available, how I consider benefits and risks, and what women should expect after treatment begins.

What Is Hormone Replacement Therapy?

Hormone replacement therapy, commonly called HRT, uses prescription hormones to treat symptoms associated with the hormonal changes of perimenopause and menopause.

You may also see it called menopausal hormone therapy, or MHT. The terms are often used interchangeably in patient education, including by ACOG.

The primary hormone used is estrogen. If a woman still has her uterus, systemic estrogen is generally combined with progesterone or a progestin to protect the uterine lining. Women who have had a hysterectomy can often use estrogen without progesterone.

HRT may be delivered through:

●   A tablet

●   A skin patch

●   A gel or spray

●   A systemic vaginal ring

●   A vaginal cream

●   A vaginal tablet or insert

●   A low-dose local vaginal ring

●   A combined estrogen-progestogen product

These forms are not interchangeable.

An estrogen patch and a low-dose vaginal estrogen tablet both contain estrogen, but they are intended to treat different concerns. The patch provides systemic treatment and can relieve hot flashes. A standard low-dose vaginal product acts mainly on vaginal and urinary tissue.

This is why I do not begin by asking, "What is the best HRT?"

I begin by asking:

What symptom are we treating, and what is the most targeted effective way to treat it?

To understand how HRT fits into the wider range of treatment options, see our guide to menopause treatment.

Why Is HRT Prescribed?

The purpose of HRT is not to make every hormone result look younger or to reverse the normal aging process.

I consider hormone therapy when changing or declining ovarian hormones are causing symptoms or health concerns that are likely to respond to treatment.

The principal reasons include:

●   Relieving moderate or severe hot flashes

●   Reducing night sweats

●   Improving sleep when temperature symptoms repeatedly cause awakenings

●   Treating vaginal dryness, burning, painful sex, and selected urinary symptoms

●   Supporting women with early, premature, or surgical menopause

●   Preventing bone loss in appropriately selected women

●   Improving daily functioning and quality of life when menopause symptoms are disruptive

Major clinical resources , including ACOG, The Menopause Society, and the NHS ,  consistently identify vasomotor symptoms, genitourinary syndrome of menopause, early estrogen loss, and bone protection as central reasons for using HRT.

HRT is not automatically required because menopause has occurred.

I still need to determine whether the symptoms are likely to be hormonal, whether hormones are likely to improve them, and whether the expected benefits outweigh the individual risks.

What Are the Signs That You May Need HRT?

The following signs do not prove that HRT is required. They indicate that a detailed menopause and treatment evaluation may be worthwhile.

Signs at a Glance

1. Hot Flashes Are Interfering With Daily Life

Hot flashes are among the clearest symptoms that may respond to systemic HRT.

A hot flash may feel like a sudden wave of heat spreading through the chest, neck, and face. It may be accompanied by sweating, flushing, a pounding heartbeat, anxiety, or chills after the heat subsides.

Some women have occasional mild warmth. Others experience intense episodes several times an hour.

The number matters, but the effect on daily life matters more.

I pay particular attention when hot flashes:

●   Interrupt meetings or work

●   Make exercise difficult

●   Require repeated clothing changes

●   Affect concentration or confidence

●   Cause social withdrawal

●   Interfere with driving or travel

●   Create anxiety about the next episode

●   Regularly interrupt sleep

Systemic HRT is the most effective treatment for bothersome hot flashes and night sweats, per The Menopause Society.

However, not every episode of sweating or heat intolerance is caused by menopause. Thyroid problems, medication effects, infection, anxiety, blood-sugar changes, and other health conditions can cause similar symptoms.

Before recommending treatment, I look at age, menstrual history, timing, medications, and the overall symptom pattern.

Dr. Kashyap's Practical Tip Track your symptoms for seven days before your appointment. Record how many hot flashes occur, whether they wake you, whether clothing or bedding becomes wet, and how you feel the following day. A short, specific record usually tells me more than "I feel hot all the time."

2. Night Sweats Are Repeatedly Disrupting Sleep

Many women first notice perimenopause through a change in sleep.

They may fall asleep normally but wake at 2 or 3 a.m. feeling hot, sweaty, restless, or unable to return to sleep. Even if the heat lasts only a few minutes, the resulting wakefulness can continue for hours.

Repeated sleep disruption can affect: energy, concentration, appetite, mood, exercise, work performance, and stress tolerance.

When night sweats are causing the awakenings, treating the vasomotor symptom may improve sleep.

Micronized progesterone may also support sleep in selected women. It can have a sedating effect, which is why oral progesterone is commonly taken at bedtime. However, it is not a universal sleeping medication, and women respond differently. Some sleep better; others feel groggy, dizzy, bloated, or emotionally unsettled.

In my practice, I also consider whether the sleep problem could be related to: sleep apnea, restless legs, anxiety or depression, pain, alcohol, thyroid disease, anemia, medications, or frequent nighttime urination.

A sudden sleep change that appears with irregular cycles, hot flashes, or night sweats is more suggestive of a hormonal contribution than insomnia occurring entirely by itself.

3. Vaginal Dryness, Painful Sex, or Urinary Symptoms Are Persisting

Some of the strongest reasons to discuss hormone treatment have nothing to do with hot flashes.

Declining estrogen can affect the vulva, vagina, urethra, and bladder. These changes are collectively called genitourinary syndrome of menopause, or GSM — a term recognized by both The Menopause Society and ACOG.

Symptoms can include: vaginal dryness, burning, itching, or irritation, reduced natural lubrication, pain during penetration, tenderness or light bleeding after sex, urinary urgency, increased frequency, burning when urine touches sensitive tissue, recurrent urinary tract infections associated with genitourinary syndrome of menopause, and ongoing bladder discomfort.

Unlike many hot flashes, which may gradually become less frequent, GSM often persists or worsens without treatment.

These symptoms do not necessarily mean that you need systemic HRT.

Local Vaginal Estrogen Is Different From Systemic HRT

Local vaginal estrogen is applied directly to the affected tissue. Standard low-dose vaginal estrogen products result in minimal systemic absorption compared with systemic estrogen.

A woman whose only concern is painful intercourse or vaginal dryness may not need a systemic patch or tablet. Local treatment may address the tissue more directly.

Estring and Femring Are Not the Same Treatment

The phrase "vaginal estrogen ring" can be confusing.

Both are inserted vaginally, but they provide different levels of estrogen exposure and are not interchangeable , a distinction laid out clearly in this GoodRx comparison of Femring and Estring. This is one I repeatedly explain in practice because the product names sound deceptively similar.

Lubricants, Moisturizers, and Vaginal Estrogen Do Different Jobs

A lubricant reduces friction during sexual activity. A vaginal moisturizer may improve everyday comfort. Vaginal estrogen treats the estrogen-related tissue changes themselves.

From My Practice

A composite patient in her late 60s had avoided intimacy for years because intercourse had become painful. She believed this was an unavoidable part of aging and had only been advised to use lubricant.

After an examination and a conversation about local therapy, she began low-dose vaginal estrogen. At follow-up, she told me she wished someone had explained much earlier that reducing friction and treating the tissue were not the same thing.

Identifying details have been changed to protect privacy.

Persistent pain, bleeding after intercourse, vulvar irritation, or urinary symptoms deserve an examination rather than years of trial-and-error with soaps and over-the-counter products.

4. You Still Have Periods, but the Pattern Suggests Perimenopause

You do not need to wait until your periods have stopped for 12 months before discussing treatment.

Perimenopause can begin years before the final menstrual period. During this transition, estrogen and progesterone may fluctuate substantially rather than declining in a smooth line.

You may notice: periods becoming closer together or farther apart, skipped cycles, heavier, lighter, longer, or shorter bleeding, new hot flashes, night sweats, worsening sleep, mood changes, more intense premenstrual symptoms, changes in migraines, vaginal or urinary symptoms, or difficulty concentrating.

HRT may be considered during perimenopause when symptoms are disruptive.

However, the plan must also account for pregnancy possibility, contraception needs, bleeding patterns, migraine history, uterus status, and individual vascular risks.

Menopausal HRT is not birth control.

Depending on the woman, I may discuss: menopausal hormone therapy, a combined hormonal contraceptive, a levonorgestrel IUD with estrogen, a cyclic regimen, a nonhormonal medication, or local vaginal treatment.

Heavy, prolonged, or unusual bleeding should not automatically be blamed on perimenopause. Bleeding after menopause should be evaluated by a healthcare provider before treatment is selected.

5. Menopause Occurred Earlier Than Expected

Early loss of ovarian function is different from reaching natural menopause at the usual age.

A formal evaluation is important when: menstrual periods stop before age 45, ovarian function is lost before age 40, both ovaries are surgically removed, chemotherapy or radiation damages ovarian function, or primary ovarian insufficiency is diagnosed.

In these situations, the discussion is not limited to immediate symptom relief.

Earlier loss of estrogen can affect bone density, vaginal and urinary health, sexual well-being, and other aspects of long-term health. Hormone therapy is generally considered for women with primary ovarian insufficiency when no contraindication exists, often until approximately the average age of natural menopause, per ACOG.

This is also one circumstance in which hormone testing may be clinically useful.

A younger woman whose cycles stop unexpectedly may need pregnancy testing, thyroid testing, prolactin, FSH and estradiol assessment, medication review, and evaluation for other causes.

Being told that you are "too young for menopause" is not a complete evaluation.

6. Bone Loss Has Become Part of the Clinical Picture

Estrogen helps maintain bone.

Systemic HRT helps prevent bone loss and reduce fracture risk while treatment is being used, per NHS guidance on the benefits and risks of HRT. For an eligible woman who also has bothersome menopause symptoms, it may offer both symptom relief and skeletal protection. The protective effect gradually diminishes after treatment is discontinued, so long-term bone health should continue to be addressed through lifestyle measures and, when appropriate, other osteoporosis therapies.

The discussion becomes especially relevant with: early or surgical menopause, primary ovarian insufficiency, osteopenia, low body weight, a strong family history of osteoporosis, long-term steroid use, or a previous fragility fracture.

HRT is not automatically the best osteoporosis treatment for every postmenopausal woman. Established osteoporosis or a previous fracture may require an osteoporosis-specific medicine.

Bone care should also include resistance training, weight-bearing activity, adequate protein, appropriate calcium intake, vitamin D assessment when indicated, and fall-risk reduction.

7. Symptoms Are Affecting Your Quality of Life

A symptom does not need to be life-threatening before it deserves treatment.

I pay attention when symptoms cause a woman to: avoid meetings or public events, stop exercising, make mistakes because she is not sleeping, avoid intimacy, withdraw socially, plan every outing around bathroom access, feel unable to manage work or caregiving, or organize her entire day around symptom control.

The presence of a symptom is only part of the clinical picture.

I also need to understand its frequency, severity, duration, and effect on normal functioning.

There is no prize for enduring severe symptoms without support. But distress alone does not prove that hormones are the correct treatment. We still need to determine what is causing the problem and whether it is likely to respond to HRT.

Symptoms That Do Not Automatically Mean You Need HRT

Many midlife symptoms are real but nonspecific. They can occur during menopause, but they can also have other causes.

HRT should not be prescribed as a general weight-loss, energy, anti-aging, or wellness treatment.

Depending on the symptom pattern, I may consider: a complete blood count, thyroid testing, iron or ferritin, glucose or other metabolic markers, medication and supplement review, sleep-apnea screening, mood and anxiety assessment, or a gynecologic evaluation.

The purpose is not to order every available test. It is to avoid missing a treatable condition because menopause became the easiest explanation.

Do You Need Hormone Testing Before Starting HRT?

Usually, no.

During perimenopause, estrogen and FSH levels can change significantly. One normal result does not rule out perimenopause, and one low estrogen result does not prove that HRT is necessary.

For most women in the typical age range, the decision is based on: symptoms, menstrual history, age and menopause stage, medical history, uterus status, current medications, personal risk factors, and treatment goals.

ACOG does not generally recommend routine hormone testing before starting treatment for typical menopause symptoms because levels fluctuate substantially during the transition.

Testing may be helpful when: symptoms begin before age 45, periods stop before age 40, pregnancy is possible, the diagnosis is uncertain, thyroid or pituitary disease is suspected, testosterone treatment is being considered, or a pellet or compounded regimen has caused concerning symptoms.

In a typical perimenopause consultation, a detailed cycle and symptom history may provide more useful information than an isolated hormone panel.

Routine salivary hormone testing is not recommended because hormone levels fluctuate substantially and these tests have not been shown to reliably guide menopause treatment.

What Are the Different Types of HRT?

This is where many guides become confusing.

The term HRT describes several separate treatment decisions:

1. Estrogen-only or combined HRT

2. Systemic or local therapy

3. Sequential or continuous treatment

4. The route used to deliver the hormones

Understanding these differences makes it much easier to understand why one woman may receive a patch and progesterone while another receives only a vaginal tablet.

1. Estrogen-Only and Combined HRT

The first distinction depends mainly on whether the uterus is present.

Estrogen-Only HRT: Most commonly prescribed to women who have had a hysterectomy. Because the uterus has been removed, there is no endometrial lining that needs protection from systemic estrogen.

Combined HRT: Contains estrogen plus progesterone or a progestin. It is generally used when the uterus is present because systemic estrogen stimulates the uterine lining. Progesterone or a progestin reduces the risk of excessive thickening and endometrial cancer.

There may be individual exceptions, including certain women with a history of endometriosis, so surgical history still needs to be reviewed.

2. Systemic and Local HRT

Systemic HRT enters the bloodstream and circulates throughout the body. Used mainly for hot flashes, night sweats, menopause-related sleep disruption, broader systemic symptoms, and bone-loss prevention in appropriate women. Systemic products include tablets, patches, gels, sprays, and systemic vaginal rings.

Local Vaginal Estrogen acts mainly within vaginal and urinary tissues. Used for vaginal dryness, painful sex, burning or irritation, urinary urgency or frequency, and recurrent urinary tract infections associated with GSM. It does not treat hot flashes.

3. Sequential and Continuous Combined HRT

This is another important type distinction that is often missed.

Sequential or Cyclic HRT generally provides estrogen every day and progesterone for part of each month. It may be considered for women who are still having periods or are in earlier perimenopause. Because progesterone is taken cyclically, a scheduled withdrawal bleed may occur.

Continuous Combined HRT provides both estrogen and progesterone every day. It is more commonly used after menopause, with the aim of avoiding scheduled monthly bleeding. Irregular spotting can still occur during the first few months while the body adjusts. NHS guidance distinguishes sequential and continuous regimens according to menopause stage and bleeding pattern.

The correct regimen depends on menstrual history, bleeding, age, uterus status, contraception requirements, and personal preference.

4. Tablets, Patches, Gels, Sprays, and Rings

When systemic estrogen is appropriate, I then consider how it should be delivered.

Oral estrogen passes through the digestive system and liver before reaching the wider circulation. Estrogen delivered through a patch, gel, or spray enters through the skin and bypasses this first-pass liver metabolism.

NHS notes that the risk of blood clots is higher with HRT tablets than with patches, gels, or sprays, although the overall risk remains small. ACOG also notes that oral estrogen may have a prothrombotic effect, while transdermal estrogen has little or no effect on certain clotting markers.

My Approach to Estrogen Route

In my practice, I often consider transdermal estrogen first when systemic therapy is appropriate.

But I do not prescribe a patch automatically.

I also consider: migraine history, skin sensitivity, blood-clot and cardiovascular risks, liver or gallbladder concerns, cost, insurance coverage, availability, previous response, and whether daily or weekly treatment is more realistic.

A prescription is only useful if the woman can obtain it, afford it, tolerate it, and use it consistently. My preferred route and the reasons behind it are also explained in my complete Menopause treatment  guide.

5. Progesterone and Progestin Options

Progesterone should not be treated as an afterthought.

Its essential role in women with a uterus is to protect the uterine lining when systemic estrogen is used.

Micronized progesterone is chemically identical to the progesterone produced by the body and is available as a regulated prescription product. A woman does not need an expensive compounded program simply to receive "bioidentical" progesterone.

I commonly recommend taking oral micronized progesterone at bedtime because it may cause drowsiness.

Some women sleep better with it. Others experience: morning grogginess, bloating, breast tenderness, dizziness, mood changes, or gastrointestinal discomfort.

When this happens, I review the dose, timing, schedule, and available alternatives before concluding that all HRT is unsuitable.

What I Tell My Patients

Progesterone sensitivity does not necessarily mean that you have failed HRT. It may mean that the dose, schedule, timing, or method of uterine protection needs to change.

What Are the Benefits of HRT?

The main benefit of HRT is effective symptom relief.

When the treatment is well matched to the problem, it may help a woman sleep, work, exercise, travel, maintain intimacy, and participate in daily life more comfortably.

Benefits at a Glance

Hot Flashes and Night Sweats: Systemic HRT is the most effective available treatment for vasomotor symptoms, per The Menopause Society.

Sleep: HRT may improve sleep when awakenings are driven by hot flashes or night sweats. Progesterone may also support sleep in some women, but it is not a universal insomnia treatment.

Vaginal and Urinary Health: Local vaginal estrogen can improve dryness, irritation, painful sex, and selected urinary symptoms by treating estrogen-related tissue changes.

Bone Protection: Systemic HRT helps prevent bone loss and reduce fracture risk while it is being used. (NHS)

Quality of Life: Reducing disruptive symptoms can allow a woman to return to exercise, work, intimacy, social activities, and restorative sleep. Quality of life is a legitimate treatment outcome, not a cosmetic concern.

What Are the Risks of HRT?

I do not describe HRT as simply "safe" or "dangerous." Both descriptions are too broad.

The risk depends on: age, time since menopause, uterus status, estrogen-only or combined treatment, dose, route, duration, personal and family history, smoking, blood pressure and metabolic health, and cancer, cardiovascular, and clotting history.

A low-dose vaginal product does not have the same exposure as an oral systemic estrogen-progestogen regimen.

A healthy woman starting treatment near menopause also has a different risk profile from someone beginning systemic therapy for the first time decades later.

For most healthy, symptomatic women under 60 who do not have major breast-cancer or blood-clot risks, NHS guidance states that the benefits are likely to outweigh the risks. The Menopause Society similarly describes a generally favorable benefit-risk profile for healthy symptomatic women younger than 60 or within approximately 10 years of menopause.

Main Risks at a Glance

Blood Clots and Stroke

Both estrogen-only and combined systemic HRT are associated with a small risk of blood clots and stroke, but route and individual history matter.

Oral estrogen undergoes first-pass hepatic metabolism, which contributes to a higher risk of venous thromboembolism than transdermal estrogen.

A patch, gel, or spray may therefore be preferred when clotting risk is an important consideration, but the route does not erase a history of blood clots, stroke, or serious cardiovascular disease.

Endometrial Cancer Risk

Systemic estrogen stimulates the uterine lining.

If a woman has a uterus and uses systemic estrogen without adequate progesterone or progestin protection, the risk of endometrial hyperplasia and cancer increases.

If progesterone causes unacceptable side effects, the dose, formulation, route, or method of endometrial protection should be reassessed rather than simply discontinued.

Breast Cancer Risk

Breast-cancer risk is not identical for every type of HRT. It varies according to: whether estrogen is used alone or with a progestogen, duration, baseline breast-cancer risk, family history, alcohol use, body weight, breast density, and age.

NHS guidance describes a small increase in breast-cancer risk with combined HRT that rises with longer use and falls after treatment is stopped. Estrogen-only HRT has a different and generally lower risk pattern.

I do not apply one arbitrary time limit to every woman. At follow-up, I review why treatment is continuing, whether the dose can be reduced, whether the route remains appropriate, and whether her medical history has changed.

Regular mammogram screening is also an important part of breast health, with recommendations based on your age, personal history, and individual risk factors.

Gallbladder Disease

Oral estrogen may increase gallbladder-related risk in susceptible women. This is another reason the route of estrogen may matter when a woman has a history of gallstones or gallbladder disease.

Starting HRT After 60 vs Continuing HRT After 60

These are different clinical situations.

Starting systemic HRT before age 60 or within approximately 10 years of menopause generally carries a more favorable benefit-risk profile for an appropriate symptomatic candidate.

Starting for the first time much later requires a more cautious cardiovascular, clotting, breast, uterine, and overall health assessment.

Continuing HRT after 60 is different from starting it at 60. There is no fixed age at which every woman must stop. NHS guidance states that there is no fixed maximum duration, provided the benefits continue to outweigh the risks and treatment is regularly reviewed.

What the 2026 FDA Labeling Changes Mean

The FDA updated boxed warnings for several menopausal hormone therapy products to better reflect current evidence and distinguish between different hormone formulations and routes of administration. These changes do not mean hormone therapy is risk-free or appropriate for every woman. Individualized risk assessment remains essential when deciding whether HRT is appropriate.

This does not mean:

●   Every HRT product now has identical labeling

●   HRT has no risks

●   Every woman is an appropriate candidate

●   Cancer, clotting, stroke, or heart history no longer matters

●   Systemic estrogen can be used without uterine protection

●   Monitoring is unnecessary

The update supports more precise risk communication, not universal reassurance.

Who May Need Extra Caution or Avoid Systemic HRT?

Systemic HRT may be unsuitable or require specialist assessment when there is: unexplained vaginal bleeding, a history of certain hormone-sensitive cancers, previous blood clots or pulmonary embolism, a known clotting disorder, stroke or heart-attack history, significant liver disease, serious cardiovascular disease, pregnancy, or a complex medical history that changes the benefit-risk balance.

These concerns are also highlighted by ACOG.

This does not mean symptoms must remain untreated.

A woman who cannot use systemic HRT may still have options such as nonhormonal hot-flash medication, vaginal moisturizers, pelvic floor treatment, or selected local therapies.

"Systemic HRT is not appropriate" should not become "nothing can be done."

What Side Effects Can HRT Cause?

Side effects and serious risks are not the same thing.

Many early effects are mild and improve as the body adjusts.

Common side effects may include: breast tenderness, bloating or mild fluid retention, headache, nausea, light spotting, patch irritation, drowsiness or dizziness with progesterone, or mood changes.

NHS advises that many side effects improve over time and recommends continuing treatment for approximately three months where possible before concluding that it is unsuitable, unless a significant concern develops.

Early Puffiness Does Not Automatically Mean Fat Gain

Temporary bloating, breast fullness, or fluid retention may occur after starting treatment. This is not the same as gaining a substantial amount of body fat over several days.

Persistent swelling, significant ankle swelling, worsening breathlessness, or rapidly progressive symptoms need medical evaluation.

What Should You Expect After Starting HRT?

HRT is a process, not a light switch.

Some women notice improvement within days or weeks. Others need more time, a different dose, another estrogen route, a change in progesterone, or additional vaginal treatment.

I recommend setting two or three measurable goals before starting. For example: reduce night sweats from five each night to one, sleep for six uninterrupted hours, complete a workday without disruptive hot flashes, resume comfortable sexual activity, reduce urinary urgency, or return to regular exercise.

NHS notes that HRT may take up to three months to work fully.

Your Friend Is Not the Control Group

Two women can use the same prescription and have completely different experiences. Absorption, metabolism, progesterone sensitivity, medical history, stress, sleep, medications, and treatment goals all differ.

A prescription that helped a friend is not automatically the right prescription for you.

The first prescription is often not the final prescription.

Follow-Up and Monitoring

I do not treat HRT as a "set it and forget it" prescription.

A new or changed regimen should generally be reviewed after the initial adjustment period. Once treatment is stable, it should still be reassessed periodically.

During follow-up, I review: whether the target symptoms have improved, side effects, bleeding, medication adherence, whether the dose remains appropriate, whether the route is practical, changes in medical history, bone-health needs, whether systemic therapy is still necessary, and whether local treatment would better address remaining symptoms.

Practical HRT Questions I Commonly Answer

Are Bioidentical Hormones Better?

The word bioidentical describes hormones that have the same chemical structure as hormones produced by the body.

The term "bioidentical" describes chemical structure rather than safety or effectiveness. It should not be interpreted as meaning that a product is inherently safer, more natural, or more effective than other FDA-approved hormone therapies.

FDA-approved estradiol and micronized progesterone are available in body-identical forms. You do not automatically need compounded hormones to receive bioidentical treatment.

ACOG recommends FDA-approved products over routinely compounded menopausal hormones because approved products have standardized manufacturing, dosing, quality controls, and prescribing information.

Compounding may have a legitimate role when a specific dose, formulation, or allergy cannot be addressed with an available approved product. It should not automatically be presented as safer, more natural, or risk-free.

What About Hormone Pellets?

Pellets are small implants placed under the skin to release hormones over several months.

Some women value the convenience. However: the dose cannot be reduced quickly, treatment cannot be stopped as easily as a patch or tablet, exposure may continue for months, side effects can be difficult to reverse, supraphysiologic testosterone levels may occur, increasing the likelihood of androgenic side effects, many pellet products are compounded, and cost may not be covered by insurance.

Pellets are not my automatic first option for a woman beginning HRT. Convenience matters, but so does the ability to change course.

Does Low Libido Mean You Need Testosterone?

Not automatically.

Low desire may be affected by: vaginal dryness, painful sex, medications, depression, poor sleep, stress, relationship concerns, a partner's health, or other medical conditions.

The strongest evidence-based indication for testosterone therapy in women is carefully diagnosed hypoactive sexual desire disorder (HSDD) in selected postmenopausal women.

It should not be prescribed as a general treatment for fatigue, weight gain, brain fog, muscle building, or anti-aging.

There is currently no female-specific FDA-approved testosterone product in the United States, so treatment requires careful dosing and monitoring.

What if My Estrogen Patch Is Unavailable?

A patch shortage should not bring treatment to an abrupt halt.

Possible alternatives may include: another patch brand or strength, estrogen gel, estrogen spray, oral estradiol, or a systemic vaginal ring.

Dose conversion is not always one-to-one. Do not switch routes using an online conversion chart. The prescribing clinician should convert the treatment and reconsider whether the new route changes any safety consideration.

Does HRT Have to Be Expensive?

No.

Generic FDA-approved options are available for many estradiol patches, oral products, progesterone capsules, and vaginal estrogen treatments.

A costly subscription, pellet program, compounded package, or large direct-to-consumer hormone panel is not required for legitimate menopause treatment.

Cost and insurance coverage are valid parts of selecting a treatment. A prescription cannot help if a patient cannot afford or obtain it.

What if HRT Is Not Right for You?

Not using systemic HRT does not mean accepting untreated symptoms.

Depending on the concern, alternatives may include: certain SSRIs or SNRIs, low-dose paroxetine, gabapentin, fezolinetant, elinzanetant, vaginal moisturizers and lubricants, vaginal DHEA, ospemifene, pelvic floor physical therapy, cognitive behavioral therapy, or sleep-focused treatment.

"No estrogen" is not a complete treatment plan. The alternative should be matched to the symptom just as carefully as HRT would be.

Not using systemic HRT does not mean accepting untreated symptoms. Depending on the concern, natural menopause treatments and other nonhormonal approaches may also help manage certain symptoms.

Questions to Ask at Your HRT Appointment

• A productive consultation goes beyond asking, "Can I have hormones?"
• Consider asking: Which symptoms are most likely related to menopause?
• Could another condition be contributing?
• Do I need systemic treatment or local vaginal treatment?
• Do I need estrogen alone or combined HRT?
• Would a sequential or continuous regimen suit me?
• Do I need progesterone because I still have my uterus?
• Would a patch, gel, spray, tablet, or ring fit me better?
• Do I still need contraception?
• Do I need any testing before starting?
• What are my personal risks? What improvement should I expect?
• How long should I try the first regimen? Which side effects are common?
• When will treatment be reviewed?
• What are my nonhormonal options?
• Is the product FDA-approved or compounded?
• What will my insurance cover?

Before the appointment, bring: recent menstrual dates, changes in cycle length or flow, a symptom record, current medications and supplements, contraception information, previous hormone use and side effects, cancer, clotting, cardiovascular, and bone history, and your main treatment goals.

When Should You Seek Prompt Medical Care?

Contact a HRT Specialist promptly or seek urgent care for: chest pain, sudden shortness of breath, one-sided leg swelling or pain, sudden severe headache, new weakness or numbness, difficulty speaking, new vision loss, very heavy bleeding, unexplained bleeding after menopause, a new breast lump, yellowing of the skin or eyes, or severe depression or suicidal thoughts.

Do not attempt to manage these symptoms by adjusting hormone doses yourself.

Conclusion

There is no single sign that proves you need hormone replacement therapy. Instead, the decision is based on understanding which symptoms are truly related to menopause, whether hormone therapy is likely to help, and whether the expected benefits outweigh the individual risks. What I have instead is a process: separating the symptoms that are genuinely hormone-driven from the ones that only look that way, matching the treatment to the specific problem rather than to the general complaint of "not feeling like myself," and reviewing the plan over time rather than treating the first prescription as the final word.

If you take one thing from this guide, let it be this: the right question isn't "do I have enough symptoms to qualify," it's "are these symptoms taking something from my life, and is there a safe, targeted way to treat them." For most women asking that second question, the answer is yes ,  and the path to get there starts with a real conversation, not a checklist.

HRT & Menopause Terms Explained

• Hormone Replacement Therapy (HRT): Prescription hormones used to treat symptoms linked to hormonal changes during perimenopause and menopause.
• Menopausal Hormone Therapy (MHT): Another term commonly used for hormone replacement therapy.
• Perimenopause: The transition before menopause when hormone levels fluctuate and menstrual cycles may become irregular.
• Menopause: The stage when menstrual periods have permanently stopped, typically diagnosed after 12 consecutive months without a period.
• Postmenopause: The stage of life after menopause.
• Estrogen: A primary reproductive hormone that declines during menopause and is commonly used in HRT to treat symptoms such as hot flashes and night sweats.
• Progesterone: A hormone used with systemic estrogen to help protect the uterine lining when the uterus is present.
• Progestin: A synthetic form of progesterone used for uterine protection in some HRT regimens.
• Systemic HRT: Hormone treatment that enters the bloodstream and affects the body more broadly. It is mainly used for symptoms such as hot flashes and night sweats.
• Local Vaginal Estrogen: Low-dose estrogen applied directly to vaginal and urinary tissues to treat symptoms such as dryness, irritation, painful sex, and selected urinary symptoms.
• Genitourinary Syndrome of Menopause (GSM): A collection of vaginal and urinary symptoms caused by declining estrogen, including dryness, burning, painful sex, and urinary problems.
• Vasomotor Symptoms: Menopause-related hot flashes and night sweats caused by changes in the body's temperature-regulation system.
• Transdermal Estrogen: Estrogen delivered through the skin using a patch, gel, or spray.
• Oral Estrogen: Estrogen taken as a tablet and processed through the digestive system and liver before reaching the bloodstream.
• Estrogen-Only HRT: Systemic estrogen therapy generally used when the uterus has been removed and endometrial protection is not required.
• Combined HRT: HRT containing estrogen plus progesterone or a progestin, generally used when the uterus is present.
• Sequential or Cyclic HRT: A regimen in which estrogen is taken continuously while progesterone or a progestin is taken during part of each month. A scheduled bleed may occur.
• Continuous Combined HRT: A regimen in which estrogen and progesterone or a progestin are taken every day, generally after menopause.
• Micronized Progesterone: Prescription progesterone that is chemically identical to the progesterone produced by the body.
• Levonorgestrel-Releasing IUD: An intrauterine device that can provide uterine protection and may also help with contraception and bleeding control.
• Primary Ovarian Insufficiency (POI): Loss or reduced function of ovarian activity before the usual age of menopause, particularly when ovarian function is lost before age 40.
• Early Menopause: Menopause occurring before age 45.
• Surgical Menopause: Menopause caused by surgical removal of both ovaries, resulting in an abrupt loss of ovarian hormones.
• Osteopenia: Lower-than-normal bone density that is not yet severe enough to be classified as osteoporosis.
• Osteoporosis: A condition in which bones become weaker and more likely to fracture.
• Endometrial Lining: The inner lining of the uterus. Systemic estrogen can stimulate this lining, which is why progesterone or a progestin is generally needed when the uterus is present.
• Endometrial Hyperplasia: Abnormal thickening of the uterine lining, which can occur when systemic estrogen is not adequately balanced with progesterone or a progestin.
• Venous Thromboembolism (VTE): Blood clots in the veins, including deep vein thrombosis and pulmonary embolism.
• Transdermal Route: Delivery of medication through the skin rather than through the digestive system.
• First-Pass Metabolism: The processing of an oral medication by the digestive system and liver before it reaches the wider circulation.
• Bioidentical Hormones: Hormones that have the same chemical structure as hormones naturally produced by the body. The term does not automatically mean safer or more effective.
• Compounded Hormones: Hormone preparations specially mixed or formulated by a compounding pharmacy rather than manufactured as standard approved products.
• Hormone Pellets: Small implants placed under the skin that release hormones over an extended period.
• Hypoactive Sexual Desire Disorder (HSDD): A persistent lack of sexual desire that causes significant distress and may be considered for carefully selected testosterone treatment.
• Testosterone Therapy: Treatment using testosterone. In women, it is not recommended as a general treatment for fatigue, weight gain, brain fog, muscle building, or anti-aging.
• Hormone Testing: Blood or other hormone measurements used in selected situations to help evaluate menopause-related concerns. Routine testing is not generally required for typical menopause symptoms.
• FSH (Follicle-Stimulating Hormone): A hormone involved in ovarian function that may be measured when the timing or cause of menopause is uncertain.
• Estradiol: A form of estrogen that may be measured in selected clinical situations and is also used in prescription HRT.
• Nonhormonal Treatment: Treatments that do not contain menopausal hormones and may be used when HRT is unsuitable or when a woman prefers another approach.
• Vaginal Moisturizer: A product used regularly to improve everyday vaginal moisture and comfort.
• Vaginal Lubricant: A product used during sexual activity to reduce friction. It does not treat the underlying estrogen-related tissue changes.
• Vaginal DHEA: A local vaginal treatment that may be used for certain menopause-related vaginal symptoms.
• Ospemifene: A non-estrogen oral treatment that may be used for certain menopause-related painful-sex symptoms.
• Pelvic Floor Physical Therapy: Therapy focused on the muscles and structures supporting the pelvic organs and may help with selected pelvic or sexual symptoms.
• Compounded Testosterone: Testosterone prepared by a compounding pharmacy rather than supplied as a standard approved product.
• FDA-Approved HRT: Hormone therapy products that have undergone regulatory review for quality, safety, effectiveness, and standardized dosing.
• Benefit-Risk Assessment: The clinical process of weighing the potential benefits of HRT against a woman's individual risks and medical history.
• Vaginal Bleeding After Menopause: Bleeding occurring after menopause that should be medically evaluated rather than automatically attributed to menopause or HRT.

References and Further Reading

1. The Menopause Society: Hormone Therapy

2. NHS: Hormone Replacement Therapy

3. NHS: Types of Hormone Replacement Therapy

4. NHS: Benefits and Risks of HRT

5. NHS: Side Effects of HRT

6. ACOG: Hormone Therapy for Menopause

7. ACOG: Hormone Testing Before Hormone Therapy

8. ACOG: Route of Estrogen and Blood-Clot Risk

9. ACOG: Compounded Bioidentical Menopausal Hormone Therapy

10. ACOG: Hormone Therapy in Primary Ovarian Insufficiency

11. FDA: Menopausal Hormone Therapies With Updated Prescribing Information (Feb. 12, 2026) (updated citation — see verification notes below)

12. GoodRx: Femring vs. Estring for Menopause Symptoms (new addition — supports the Estring/Femring comparison)

This article is for educational purposes and does not replace individualized medical evaluation, diagnosis, or treatment. Hormone therapy should be prescribed and monitored by a qualified healthcare professional after reviewing symptoms, medical history, individual risks, and treatment goals. Patient examples are composites, with identifying details changed to protect privacy.